Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer

被引：1
作者：
Lu, Kevin [1 ]
Husain, Hatim [1 ,2 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA USA
[2] Univ Calif San Diego, Div Med Oncol, 3855 Hlth Sci 3011, La Jolla, CA 92093 USA
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2023年 / 12卷 / 06期
关键词：
Non-small cell lung cancer (NSCLC); KRAS G12C; adagrasib; sotorasib; BRAIN METASTASES; NSCLC;
D O I：
10.21037/tlcr-23-26
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1335 / 1337
页数：3
相关论文
共 12 条
  • [1] [Anonymous], 2022, FDA GRANTS ACC APPR
  • [2] Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
    Ballard, Peter
    Yates, James W. T.
    Yang, Zhenfan
    Kim, Dong-Wan
    Yang, James Chih-Hsin
    Cantarini, Mireille
    Pickup, Kathryn
    Jordan, Angela
    Hickey, Mike
    Grist, Matthew
    Box, Matthew
    Johnstrom, Peter
    Varnas, Katarina
    Malmquist, Jonas
    Thress, Kenneth S.
    Janne, Pasi A.
    Cross, Darren
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (20) : 5130 - 5140
  • [3] Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
    Cui, Wanyuan
    Franchini, Fanny
    Alexander, Marliese
    Officer, Ann
    Wong, Hui-Li
    IJzerman, Maarten
    Desai, Jayesh
    Solomon, Benjamin J.
    [J]. LUNG CANCER, 2020, 146 : 310 - 317
  • [4] Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial
    Goldberg, Sarah B.
    Schalper, Kurt A.
    Gettinger, Scott N.
    Mahajan, Amit
    Herbst, Roy S.
    Chiang, Anne C.
    Lilenbaum, Rogerio
    Wilson, Frederick H.
    Omay, Sacit Bulent
    Yu, James B.
    Jilaveanu, Lucia
    Thuy Tran
    Pavlik, Kira
    Rowen, Elin
    Gerrish, Heather
    Komlo, Annette
    Gupta, Richa
    Wyatt, Hailey
    Ribeiro, Matthew
    Kluger, Yuval
    Zhou, Geyu
    Wei, Wei
    Chiang, Veronica L.
    Kluger, Harriet M.
    [J]. LANCET ONCOLOGY, 2020, 21 (05) : 655 - 663
  • [5] Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
    Jaenne, Pasi A.
    Riely, Gregory J.
    Gadgeel, Shirish M.
    Heist, Rebecca S.
    Ou, Sai-Hong I.
    Pacheco, Jose M.
    Johnson, Melissa L.
    Sabari, Joshua K.
    Leventakos, Konstantinos
    Yau, Edwin
    Bazhenova, Lyudmila
    Negrao, Marcelo V.
    Pennell, Nathan A.
    Zhang, Jun
    Anderes, Kenna
    Der-Torossian, Hirak
    Kheoh, Thian
    Velastegui, Karen
    Yan, Xiaohong
    Christensen, James G.
    Chao, Richard C.
    Spira, Alexander I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (02) : 120 - 131
  • [6] Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases
    Koster, Kira-Lee
    Appenzeller, Christina
    Lauber, Arno
    Fruh, Martin
    Schmid, Sabine
    [J]. CASE REPORTS IN ONCOLOGY, 2022, 15 (02): : 720 - 725
  • [7] Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
    Palma, Gabriela
    Khurshid, Faisal
    Lu, Kevin
    Woodward, Brian
    Husain, Hatim
    [J]. NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [8] Ramalingam S, 2021, J THORAC ONCOL, V16, pS1123
  • [9] Sabari JK, 2022, J CLIN ONCOL, V40
  • [10] Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer
    Sabari, Joshua K.
    Velcheti, Vamsidhar
    Shimizu, Kazuhide
    Strickland, Matthew R.
    Heist, Rebecca S.
    Singh, Mohini
    Nayyar, Naema
    Giobbie-Hurder, Anita
    Digumarthy, Subba R.
    Gainor, Justin F.
    Rajan, Anant P.
    Nieblas-Bedolla, Edwin
    Burns, Aaron C.
    Hallin, Jill
    Olson, Peter
    Christensen, James G.
    Kurz, Sylvia C.
    Brastianos, Priscilla K.
    Wakimoto, Hiroaki
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (15) : 3318 - 3328
12